Grupo Espanol de Investigacion en Sarcomas   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Madrid Spain (1994)

Organization Overview

First Clinical Trial
2004
NCT00103168
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Grupo Español de Investigacion en Sarcomas | Grupo Espanol de Investigacion en Sarcomas

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Chondrosarcoma (Phase 2)

Desmoplastic Small Round Cell Tumor (Phase 2)

Drug-Related Side Effects and Adverse Reactions (Phase 2)

Fibromatosis, Aggressive (Phase 2)

Gastrointestinal Stromal Tumors (Phase 3)

Leiomyosarcoma (Phase 2)

Liposarcoma (Phase 2)

Liposarcoma, Myxoid (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Fibrous Tissue (Phase 2)

Neuroectodermal Tumors, Primitive, Peripheral (Phase 2)

Osteosarcoma (Phase 2)

Sarcoma (Phase 3)

Sarcoma, Ewing (Phase 2)

Solitary Fibrous Tumors (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 19
  • # of Trial APIs: 20